Targeting eIF4A-Dependent Translation of KRAS Signaling Molecules-Reference-Cited by-同舟云学术

Targeting eIF4A-Dependent Translation of KRAS Signaling Molecules

Published:2021-02-25 Issue:8 Volume:81 Page:2002-2014
ISSN:0008-5472
Container-title:Cancer Research
language:en
Short-container-title:Cancer Res

Author:

Singh Kamini,Lin Jianan,Lecomte Nicolas,Mohan Prathibha^ORCID,Gokce Askan,Sanghvi Viraj R.^ORCID,Jiang Man,Grbovic-Huezo Olivera^ORCID,Burčul Antonija,Stark Stefan G.,Romesser Paul B.^ORCID,Chang Qing,Melchor Jerry P.,Beyer Rachel K.,Duggan Mark,Fukase Yoshiyuki^ORCID,Yang Guangli,Ouerfelli Ouathek^ORCID,Viale Agnes,de Stanchina Elisa,Stamford Andrew W.,Meinke Peter T.,Rätsch Gunnar,Leach Steven D.,Ouyang Zhengqing^ORCID,Wendel Hans-Guido

Funder

NIHNCIMemorial Sloan Kettering Cancer CenterNCIMemorial Sloan Kettering Cancer Center

MSKCC Core Grant

NIH

ETH Zürich

CCSG

NCI

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Exon Junction Complex component EIF4A3 plays a splicing-linked oncogenic role in pancreatic ductal adenocarcinoma;Cancer Gene Therapy;2024-09-04

2. GRP78 inhibitor YUM70 upregulates 4E-BP1 and suppresses c-MYC expression and viability of oncogenic c-MYC tumors;Neoplasia;2024-09

3. 5’UTR translational inhibition of neuroblastoma dependency factors using the CR-1-31-B rocaglate;2024-08-30

4. Silvestrol, a potent anticancer agent with unfavourable pharmacokinetics: Current knowledge on its pharmacological properties and future directions for the development of novel drugs;Biomedicine & Pharmacotherapy;2024-08

5. Combined HDAC and eIF4A inhibition: A novel epigenetic therapy for pancreatic adenocarcinoma;2024-07-02